Welcome to our dedicated page for Chemed SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chemed Corporation filings document a Delaware operating company whose capital stock trades on the NYSE under CHE and whose business is conducted through VITAS Healthcare and Roto-Rooter. Current reports disclose segment operating results for hospice and palliative care services, plumbing and drain cleaning services, patient-care metrics, service revenue and capital allocation.
Chemed's regulatory record also includes 8-K disclosures for earnings releases, Regulation FD updates, senior secured revolving credit facilities and related direct financial obligations. Proxy materials cover director elections, executive compensation, pay-versus-performance data and governance matters, while event reports record leadership changes within the VITAS business.
Chemed Corporation reported voting results from its annual meeting of stockholders held on May 18, 2026. All director nominees were elected, with support levels generally above ten million votes for each candidate and broker non-votes of 769,580 on each director item.
Stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent accountants for the year ending December 31, 2026, with 11,562,294 votes for and 523,129 against. However, the non-binding proposal to approve the company’s executive compensation program was not approved, receiving 4,383,683 votes for and 6,926,656 votes against, with 769,580 broker non-votes.
WALSH GEORGE J III reported acquisition or exercise transactions in this Form 4 filing.
CHEMED CORP director WALSH GEORGE J III reported a stock award of 386 shares of Capital Stock. The shares were granted at a reported price of $440.77 per share as a compensation-related award. Following this grant, he directly holds 3,709 shares. A separate entry shows indirect ownership of 434 shares held by his spouse, reflecting family holdings rather than a new market trade.
CHEMED CORP director John Meredith Mount Jr. reported a compensation-related stock award of capital stock. He received 386 shares on May 18, 2026, described as an award of stock in the footnotes. The grant was valued at $440.77 per share for reporting purposes. After this award, his direct holdings increased to 1,316 shares of Chemed capital stock. This is a non-derivative, grant/award acquisition rather than an open-market purchase or sale.
CHEMED CORP director Eileen P. McCarthy received an award of 386 shares of Capital Stock as compensation. The shares were granted on May 18, 2026 at a value of $440.77 per share, described as an award of stock.
Following this non-market acquisition, McCarthy directly holds 1,241 shares of CHEMED CORP Capital Stock. This transaction reflects an equity compensation grant rather than an open-market purchase, increasing her direct ownership stake in the company.
LINDELL ANDREA R reported acquisition or exercise transactions in this Form 4 filing.
CHEMED CORP director Andrea R. Lindell received an award of 386 shares of Capital Stock on May 18, 2026, valued at $440.77 per share. This was a stock grant rather than an open-market purchase. After the award, she directly holds 5,925 shares.
Heaney Christopher J reported acquisition or exercise transactions in this Form 4 filing.
CHEMED CORP director Christopher J. Heaney received an equity award of 386 shares of Capital Stock. The award, described as an “Award of stock,” was granted on May 18, 2026 at a price of $440.77 per share. Following this grant, Heaney directly owns 2,775 shares of Chemed capital stock. This is a compensation-related stock award rather than an open-market purchase or sale.
GRACE PATRICK P reported acquisition or exercise transactions in this Form 4 filing.
CHEMED CORP director Patrick P. Grace received an award of 386 shares of Capital Stock on May 18, 2026. The shares were valued at $440.77 per share in the Form 4. After this stock award, Grace held a total of 3,723 shares directly.
DeLyons Ron reported acquisition or exercise transactions in this Form 4 filing.
CHEMED CORP director Ron DeLyons received an award of 386 shares of Capital Stock on May 18, 2026. The shares were valued at $440.77 per share for the transaction. This was a grant or award, not an open-market purchase, and increased his direct holdings to 2,052 shares after the transaction.
CHEMED CORP director Patrick P. Grace sold shares in an open-market trade. On this transaction date, he sold 60 shares of Chemed Capital Stock at an average price of $425.78 per share. After the sale, he directly owned 3,337 shares, so the transaction represented only a small portion of his holdings.